Is Candida really a threat in the ICU?

Current Opinion in Critical Care

Volumn 14, Issue 5, 2008, Pages 600-604

  Blot, Stijn ^a,b,c   Dimopoulos, George ^d   Rello, Jordi ^e   Vogelaers, Dirk ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY COLLEGE GHENT   (Belgium)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Antifungals; Candida; Diagnosis; Intensive care; Mortality; Outcome

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ASPIRATION; BACTERIAL COLONIZATION; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CATHETER REMOVAL; DRUG SAFETY; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS ISOLATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MORTALITY; OPPORTUNISTIC INFECTION; PREVALENCE; PYURIA; REVIEW; SEPSIS; SEPTIC SHOCK; THERAPY DELAY; TRACHEA; URINE CULTURE; WOUND INFECTION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; CULTURE TECHNIQUES; HUMANS; INTENSIVE CARE UNITS; UNITED STATES;

EID: 55349131727     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830f1dff     Document Type: Review

References (66)

1. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 2004; 64:2159-2175.
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167:1247-1251.
3. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630.
4. Laupland KB, Davies HD, Church DL, et al. Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study. Infection 2004; 32:59-64.
5. Hoste EA, Blot SI, Lameire NH, et al. Effect of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. J Am Soc Nephrol 2004; 15:454-462.
6. Petti CA, Sanders LL, Trivette SL, et al. Postoperative bacteremia secondary to surgical site infection. Clin Infect Dis 2002; 34:305-308.
7. Laupland KB, Zygun DA, Davies HD, et al. Population-based assessment of intensive care unit-acquired bloodstream infections in adults: incidence, risk factors, and associated mortality rate. Crit Care Med 2002; 30:2462-2467.
8. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005; 41:1591-1598.
9. Colombo AL, Guimaraes T, Silva LR, et al. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007; 28:570-576.
10. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317.
11. De Waele JJ, Hoste EA, Blot SI. Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death. Surg Infect (Larchmt) 2008; 9:171-177.
12. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50:302-310.
13. Azoulay E, Timsit JF, Tafflet M, et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006; 129:110-117.
14. el-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, nonneutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156:583-590.
15. Rello J, Esandi ME, Diaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114:146-149.
16. Azoulay E, Cohen Y, Zahar JR, et al. Practices in nonneutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med 2004; 30:1384-1389.
17. Xie GH, Fang XM, Fang Q, et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care 2008; 12:R5.
18. Blot S, Vandewoude K, Vogelaers D. Discriminating invasive fungal infection from colonization. Crit Care 2008; 12:412.
19. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10:R31.
20. Dimopoulos G, Piagnerelli M, Berre J, et al. Post mortem examination in the intensive care unit: still useful? Intensive Care Med 2004; 30:2080-2085.
21. Sawyer RG, Rosenlof LK, Adams RB, et al. Peritonitis into the 1990s: changing pathogens and changing strategies in the critically ill. Am Surg 1992; 58:82-87.
22. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998; 22:158-163.
23. Rotstein OD, Pruett TL, Simmons RL Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 1986; 29:247-250.
24. Sotto A, Lefrant JY, Fabbro-Peray P, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50:569-576.
25. Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med 2006; 34:902-903.
26. Sandven P, Giercksky KE. Yeast colonization in surgical patients with intraabdominal perforations. Eur J Clin Microbiol Infect Dis 2001; 20:475-481.
27. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65:1611-1620.
28. Blot S, Vandewoude K, De Waele J. Candida peritonitis. Curr Opin Crit Care 2007; 13:195-199. This review article outlines the pathogenic significance of intra-abdominal cultures growing Candida spp. and proposes an algorithm to initiate antifungal therapy.
29. Alvarez-Lerma F, Nolla-Salas J, Leon C, et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med 2003; 29:1069-1076.
30. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:19-24.
31. Sobel JD, Lundstrom T. Management of Candiduria. Curr Urol Rep 2001; 2:321-325.
32. Dimopoulos G, Velegraki A, Pefanis A, Karabinis A. Candiduria in critically ill patients: an early candidemia marker when coupled with multiple blood specimens PCR assays? Hepatogastroenterology 2007; 54:354-358. This prospective study evaluates the value of PCR assays in candiduric patients to predict candidemia. This approach was demonstrated to have an absolute negative predictive value, but a rather low positive predictive value.
33. Toya SP, Schraufnagel DE, Tzelepis GE. Candiduria in intensive care units: association with heavy colonization and candidaemia. J Hosp Infect 2007; 66:201-206.
34. Ballard J, Edelman L, Saffle J, et al. Positive fungal cultures in burn patients: a multicenter review. J Burn Care Res 2008; 29:213-221. This large multicenter study points out the incidence and clinical relevance of fungal colonization and infection in a burn population. The low mortality in untreated patients indicates that fungal cultures do not necessarily request for antifungal therapy.
35. Nasser S, Mabrouk A, Maher A. Colonization of burn wounds in Ain Shams University Burn Unit. Burns 2003; 29:229-233.
36. Desai MH, Herndon DN, Abston S. Candida infection in massively burned patients. J Trauma 1987; 27:1186-1188.
37. McKinnon PS, Goff DA, Kern JW, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136:1401-1408; discussion 1409.
38. Agvald-Öhman C, Klingspor L, Hjelmqvist H, Edlund C. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40:145-153. Monocenter study evaluating the clinical value of the Candida colonization index in critically ill patients. In regression analysis, a relationship between a higher colonization density and subsequent invasive candidiasis was found. However, a clear cut-off value useful to start pre-emptive therapy could not be defined.
39. Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis 2007; 11:239-244.
40. Charles PE, Dalle F, Aube H, et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005; 31:393-400.
41. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-737.
42. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29:2162-2169.
43. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30.
44. Voss A, le Noble JL, Verduyn Lunel FM, et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25:8-11.
45. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus nonalbicans candidemia in non-neutropenic patients. Ann Pharmacother 2007; 41:568-573.
46. Blot S, Vandewoude K, Hoste E, et al. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J Hosp Infect 2001; 47:308-313.
47. Dimopoulos G, Ntziora F, Rachiotis G, et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106:523-529; table of contents.
48. Cheng MF, Yang YL, Yao TJ, et al. Risk factors for fatal candidemia caused by Candida albicans and nonalbicans Candida species. BMC Infect Dis 2005; 5:22.
49. Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on longterm trends in candidal ecology. J Antimicrob Chemother 2006; 58:474-477.
50. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-623.
51. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6:21.
52. Ruan SY, Lee LN, Jerng JS, et al. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008; 14:136-140. A cohort study of ICU patients with Candida glabrata candidemia. Nearly 70% of these patients received fluconazole prior to the development of the candidemia, thereby assuming a role for broad-spectrum antifungals in the empiric treatment of patients previously exposed to azoles.
53. Bassetti M, Trecarichi EM, Righi E, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58:325-331.
54. Blot S, De Bacquer D, Hoste E, et al. Influence of matching for exposure time on estimates of attributable mortality caused by nosocomial bacteremia in critically ill patients. Infect Control Hosp Epidemiol 2005; 26:352-356.
55. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007; 20:391-396.
56. Hoerauf A, Hammer S, Muller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26:2010-2015.
57. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37:208-213.
58. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-1078.
59. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25:419-425.
60. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480-485.
61. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17:168-175.
62. Blot SI, Hoste EA, Vandewoude KH, Colardyn FA. Estimates of attributable mortality of systemic Candida infection in the ICU. J Crit Care 2003; 18:130-131; author reply 131.
63. Blot S. Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect 2008; 14:5-13. This review article summarizes essentials to limit the burden of severe nosocomial infection. Issues in prevention of cross-transmission over strategies to select empiric therapy to adequate source control are appraised.
64. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645.
65. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613-618. This population-based surveillance study demonstrates a significant relationship between empiric antifungal therapy and increased survival. Failure to initiate antifungal therapy prior to the availability of culture results was an independent predictor of death.
66. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008; 46:890-896. This prospective trial reports promising results about the value of a PCR assay technique in daily ICU practice for shortening the diagnosis time of candidemia.